

CITATION REPORT

List of articles citing

Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

DOI: 10.1007/s41669-018-0080-5

PharmacoEconomics - Open, 2019, 3, 43-54.

Source: <https://exaly.com/paper-pdf/71821240/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	Nivolumab plus ipilimumab cost effective for advanced melanoma. <i>PharmacoEconomics & Outcomes News</i> , 2018 , 804, 22-22	0.1	
13	Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 14	7.8	5
12	A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments. <i>Applied Health Economics and Health Policy</i> , 2019 , 17, 771-780	3.4	19
11	Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 780-785	2.8	
10	Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada. <i>PharmacoEconomics - Open</i> , 2019 , 3, 321-331	2.1	5
9	Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. <i>PharmacoEconomics - Open</i> , 2020 , 4, 343-351	2.1	1
8	Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1947-1958	7.4	2
7	Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?. <i>Value in Health</i> , 2020 , 23, 1613-1621	3.3	11
6	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020 , 80, 5427-5434	10.1	32
5	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. <i>BioDrugs</i> , 2021 , 35, 61-73	7.9	
4	Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 373-380	2.2	4
3	Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma.. <i>Value in Health</i> , 2022 , 25, 595-604	3.3	
2	A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia. 2022 , 15, 833-847		0
1	Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.		0